BidaskClub Lowers Corindus Vascular Robotics Inc (CVRS) to Strong Sell

Corindus Vascular Robotics Inc (NYSEMKT:CVRS) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Wednesday.

A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Corindus Vascular Robotics from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine cut shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Finally, Cowen and Company set a $3.00 target price on shares of Corindus Vascular Robotics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Corindus Vascular Robotics currently has a consensus rating of “Hold” and a consensus price target of $2.58.

Shares of Corindus Vascular Robotics (NYSEMKT CVRS) opened at 1.48 on Wednesday. The company’s 50-day moving average price is $1.61 and its 200-day moving average price is $1.50. The company’s market capitalization is $277.20 million. Corindus Vascular Robotics has a 52-week low of $0.40 and a 52-week high of $2.25.

Corindus Vascular Robotics (NYSEMKT:CVRS) last announced its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. Corindus Vascular Robotics had a negative net margin of 372.63% and a negative return on equity of 94.27%. The business had revenue of $2.26 million during the quarter, compared to the consensus estimate of $3.10 million. Equities research analysts forecast that Corindus Vascular Robotics will post ($0.21) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “BidaskClub Lowers Corindus Vascular Robotics Inc (CVRS) to Strong Sell” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/11/bidaskclub-lowers-corindus-vascular-robotics-inc-cvrs-to-strong-sell.html.

Several institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in shares of Corindus Vascular Robotics by 34.4% in the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock worth $276,000 after purchasing an additional 38,000 shares during the last quarter. State Street Corp grew its stake in shares of Corindus Vascular Robotics by 44.3% in the second quarter. State Street Corp now owns 926,439 shares of the medical equipment provider’s stock worth $1,724,000 after purchasing an additional 284,507 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock worth $109,000 after purchasing an additional 35,086 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Corindus Vascular Robotics by 57.6% in the second quarter. Vanguard Group Inc. now owns 3,279,185 shares of the medical equipment

A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Corindus Vascular Robotics from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine cut shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Finally, Cowen and Company set a $3.00 target price on shares of Corindus Vascular Robotics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Corindus Vascular Robotics currently has a consensus rating of “Hold” and a consensus price target of $2.58.

Shares of Corindus Vascular Robotics (NYSEMKT CVRS) opened at 1.48 on Wednesday. The company’s 50-day moving average price is $1.61 and its 200-day moving average price is $1.50. The company’s market capitalization is $277.20 million. Corindus Vascular Robotics has a 52-week low of $0.40 and a 52-week high of $2.25.

Corindus Vascular Robotics (NYSEMKT:CVRS) last announced its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. Corindus Vascular Robotics had a negative net margin of 372.63% and a negative return on equity of 94.27%. The business had revenue of $2.26 million during the quarter, compared to the consensus estimate of $3.10 million. Equities research analysts forecast that Corindus Vascular Robotics will post ($0.21) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “BidaskClub Lowers Corindus Vascular Robotics Inc (CVRS) to Strong Sell” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/11/bidaskclub-lowers-corindus-vascular-robotics-inc-cvrs-to-strong-sell.html.

Several institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in shares of Corindus Vascular Robotics by 34.4% in the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock worth $276,000 after purchasing an additional 38,000 shares during the last quarter. State Street Corp grew its stake in shares of Corindus Vascular Robotics by 44.3% in the second quarter. State Street Corp now owns 926,439 shares of the medical equipment provider’s stock worth $1,724,000 after purchasing an additional 284,507 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock worth $109,000 after purchasing an additional 35,086 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Corindus Vascular Robotics by 57.6% in the second quarter. Vanguard Group Inc. now owns 3,279,185 shares of the medical equipment provider’s stock worth $6,100,000 after purchasing an additional 1,198,384 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Corindus Vascular Robotics by 42.4% in the second quarter. Northern Trust Corp now owns 959,920 shares of the medical equipment provider’s stock worth $1,786,000 after purchasing an additional 285,811 shares during the last quarter.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply